Xpention Genetics, Inc. Enters Into Contract With AMC Cancer Research Center
10/19/2005 5:09:14 PM
CONIFER, Colo.--(BUSINESS WIRE)--June 20, 2005--Xpention Genetics, Inc. (OTC BB:XPNG.OB) and AMC Cancer Center in Denver, Colorado sign contract to develop an immunological cancer test for use on canines. The cancer test will use Xpention's licensed p65 technology from the University of Texas MD Anderson Cancer Center. P65 is a promising marker for the early detection of malignant tumor formation and a useful tool for monitoring therapy and remission. Levels of p65 also appear to have a direct correlation to tumor mass/size.
Founded in 1904, AMC Cancer Research Center is a not-for-profit research institute dedicated to the prevention and control of cancer and other chronic diseases.
comments powered by